SAN FRANCISCO, July 19, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Audentes. The shares are expected to begin trading on The NASDAQ Global Market on July 20, 2016 under the symbol "BOLD." In addition, the underwriters have been granted a 30-day option to purchase up to an additional 750,000 shares of common stock.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as a co-manager.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on July 19, 2016. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (631) 274-2806; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.